Purpose: An estimated 24% -45% of patients with cancer develop brain metastases. Individualized estimation of survival for patients with brain metastasis could be useful for counseling patients on clinical outcomes and prognosis. Methods: De-identified data for 2367 patients with brain metastasis from 7 Radiation Therapy Oncology Group randomized trials were used to develop and internally validate a prognostic nomogram for estimation of survival among patients with brain metastasis. The prognostic accuracy for survival from 3 statistical approaches (Cox proportional hazards regression, recursive partitioning analysis [RPA], and random survival forests) was calculated using the concordance index. A nomogram for 12-month, 6-month, and median survival was generated using the most parsimonious model. Results: The majority of patients had lung cancer, controlled primary disease, no surgery, Karnofsky performance score (KPS) ≥ 70, and multiple brain metastases and were in RPA class II or had a Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) score of 1.25 -2.5.
A n estimated 24% -45% of all patients with cancer develop brain metastases every year. 1, 2 The most common primary tumors that metastasize to the brain are melanoma, lung, breast, and renal cancer. 2, 3 The current standard of care for patients with brain metastasis consists of whole-brain radiotherapy (WBRT) and/or stereotactic radiosurgery and/or surgery. 1, 2 However, controversy still exists regarding selection of the optimal treatment regimen.
Gaspar et al. evaluated prognostic factors associated with survival among patients with brain metastasis using recursive partitioning analysis (RPA) 4, 5 and found that age, Karnofsky performance score (KPS), status of primary disease, and metastatic spread formed 3 classes with distinct survival times. Although these classes have been validated in successive studies, Sperduto et al. developed a new prognostic scoring system called the Graded Prognostic Assessment (GPA) 6 -8 and found that age, KPS, number of brain metastases, and presence/ absence of extracranial metastasis accurately estimated prognosis. The GPA was then extended to include diagnosis-specific information (diagnosis-specific GPA [DS-GPA]), which improved its accuracy for estimating prognosis. 9 Although these classification systems have been validated in successive studies, 10 -14 RPA and DS-GPA provide group rather than individualized estimates; all patients in a class have the same clinical characteristics and, therefore, the same survival.
Additional prognostic scores have been developed for patients with brain metastasis. For those undergoing radiosurgery, 2 progonsotic systems have been developed: the score index for radiosurgery (SIR) and the basic score for brain metastasis (BS-BM). Lorenzoni et al. showed that these were more accurate than RPA in predicting survival in this patient population. 15, 16 The interval from tumor diagnosis to WBRT was the main predictor in the intracerebral control and survival rate scoring index of Rades et al. 17, 18 Individualized estimation of survival among patients with brain metastasis could be useful for counseling patients on treatment decisions and optimizing therapeutic approaches. These estimates are most useful at the time of diagnosis. Nomograms are often used for estimation of individualized cancer prognosis, 19, 20 but this approach has not been applied to brain metastasis. The purpose of this study was to develop and internally validate a nomogram for estimation of individualized survival probabilities for patients with brain metastasis with use of data from the Radiation Therapy Oncology Group (RTOG) that could be applied at the time of initial diagnosis.
Methods

Study Population
De-identified data were provided by RTOG for 7 brain metastasis randomized clinical trials spanning over 20 years (as approved by the Case Cancer Institutional Review Board): 0118, 21 0119,  22 79 -16,  23 85 -28,   24 89 -05, 25 91 -04, 26 and 95 -08. 27 These data included information on a total of 2367 patients. After removing individuals with missing information (n ¼ 17), 2350 patients were available for analysis.
Variables of Interest
For each patient, the following variables were obtained: primary site (breast, lung, skin-melanoma, gastrointestinal, renal, other), histology (adenocarcinoma, large cell, small cell, non -small cell, squamous cell, other), status of primary disease (controlled, uncontrolled), metastatic spread (brain only, brain and other sites), surgery for brain metastasis (partial or complete/gross total resection, biopsy, none), age, KPS (≥70, ,70), RTOG RPA class (I, II, III), DS-GPA score group (0-1, 1.25-2.5, 2.75-3, 3.25-4) and number of brain lesions (single, multiple, actual number of lesions). Patient selfreported history of headaches, history of seizures, and history of visual disturbance were also assessed.
Statistical Analysis
Missing variable values were imputed by the method of chained equations (MICE 28 ), which uses a regression model for each variable with missing data, using all other variables as predictors, in an iterative fashion until all missing values are predicted.
Kaplan-Meier was used to estimate overall survival, defined as time to death from any cause. Survival was further assessed with adjustment for variables of interest using Cox proportional hazards regression, 29 RPA, 30 and random survival forests (RSF). 31, 32 In the Cox model, continuous and ordinal variables were modeled with restricted cubic splines to relax the linearity assumption. In RPA, a full recursive classification tree was created and the least important splits were eliminated recursively to obtain the final subclassification tree, which minimized the model deviance. In RSF, 1000 trees were grown, terminal nodes were set to 20, and all possible split points for each variable were examined using RSF to find the optimal split solution. All other RSF arguments were left at default values.
For each statistical approach, 2 models were fit: the full model, which included all variables of interest, and the reduced model, which included all variables of interest except symptoms. Models were internally validated via 10-fold cross-validation, and individual predicted 12-month survival probabilities were generated to quantify predictive accuracy and calibration. The predictive accuracy for overall survival of the 3 statistical approaches for each of the 2 models (full and reduced) was calculated using the concordance index (CI), which is equivalent to the area under the receiveroperating characteristic curve for censored data ranging from 0.5 to 1. The significance levels for the differences in CIs of competing statistical approaches were produced from bootstrap. A final nomogram was built using the statistical model with the highest predictive accuracy for individualized estimation of survival based on the CI. Calibration of the final model was visually assessed as follows: all patients were assigned into quintiles of the nomogram-predicted 12-month survival probabilities, and within each quintile, the mean nomogram predicted 12-month survival probability was plotted against the Kaplan-Meier estimated 12-month survival. The accuracy for estimating survival of the current RPA and DS-GPA classes was directly compared with the nomogram. For some patients (n ¼ 753), the number of lesions was recorded as .1 only; to calculate the DS-GPA score in this group, the score was calculated assuming 2-3 lesions and then assuming .3 lesions. These 2 scores were averaged, providing a final DS-GPA score for these patients. All analyses were performed using R, version 2.10.0 (http://www.r-project.org/).
Results
Of the 2350 patients available for study, 2273 were deceased (96.7%). Characteristics of these patients are shown in Table 1 along with the number of patients with missing information by variable of interest. The mean age across studies is similar. The majority of patients had primary lung cancer (66%). Most patients had controlled primary disease, no surgery, KPS ≥ 70, and multiple brain metastases. Thus, most were classified as RPA class II and had a DS-GPA score of 1.25-2.5 ( Table 1 ). In addition, the vast majority of patients did not undergo surgery (data not shown); thus, this variable was not tested in the models. The overall median survival was 136 days ( 4.5 months) after randomization (95% confidence interval [CI], 126-144 days) ( Because the reduced Cox proportional hazards model had a better CI than the full Cox model, we built the nomogram to estimate 6-and 12-month survival probabilities and median survival time for the reduced model. Therefore, the nomogram included the following: primary site and histology, status of primary disease, metastatic spread, age, KPS, and number of brain lesions (Fig. 2) . The incremental accuracy for estimating survival for each of the variables is shown by the decrease in the CI when the predictor variable is removed from the existing model: age (0.018), status of primary disease (0.013), metastatic spread (0.013), primary site & histology (0.010), number of brain lesions (0.0031), and KPS (,0.001). The impact of study registration year was also tested and did not have any effect on the CI. The final Cox model was well calibrated (Fig. 3) ; for each quintile group, the estimated versus observed 12-month survival probabilities intersected the 45-degree line, demonstrating that the predicted value approximated the observed value within a 95% confidence interval.
We also compared the estimations from the nomogram with those from the RPA classes (Fig. 4) 4,5 or the DS-GPA score groups (Fig. 5) . 9 We found that the nomogram-estimated 12-month survival probabilities are heterogeneously distributed within each RPA class or DS-GPA score group. These results indicate the potential use of individualized prognostic estimation obtained from the nomogram versus the group-wise prognostic estimations obtained from either the RPA or the DS-GPA.
Discussion
The objective of this analysis was to develop and internally validate an individualized prognostic nomogram for patients with brain metastasis. We found that the best fitting model was the Cox proportional hazards survival model and included primary site and histology, status of primary disease, metastatic spread, age, KPS, and number of brain lesions. Thus, the nomogram was built using this model (Fig. 2) .
The RPA brain metastasis article 5 used data from 3 RTOG trials (79 -16, 85 -28, and 89 -05) and was based on KPS, status of primary disease, age, and metastatic spread. These were then validated using data from 91 -04 and compared with the RTOG historical database. 4 We showed that, although the original 4 variables included in the Gaspar RPA classes were important predictors, primary site and histology and number of brain lesions were also important for accuracy of survival estimation. In comparison with other variables, KPS provided the least amount of incremental accuracy for estimating survival, which might be accounted for by bias and interobserver variability.
The original RPA class system has been externally validated using other groups of patients with brain metastasis. Agboola et al. 11 applied these classes to patients with brain metastases who had undergone resection and WBRT. They found that survival was significantly associated with RPA class assignment. Two additional studies in patients with brain metastases from renal cell carcinoma 12 and small cell lung cancer 13 have also validated this finding. In addition, Sanghavi et al. 14 showed improvement in survival with radiosurgery for all RPA classes, but each RPA class had separate survival from the other classes. However, in most of these studies, the majority of patients tended to fall primarily into class II, which is defined by lack of characteristics of class I or class III. Thus, approaches to studying subclassification of patients in these RPA classes are warranted.
The original GPA external validation analysis by Sperduto et al. used data from 5 RTOG trials: 79 -16, 85 -28, 89 -05, and 95 -08. The GPA scores were based on age, KPS, number of brain metastases, and presence/absence of extracranial metastases. 6 Recently, these scores have been extended to include information about primary site and histology (DS-GPA) 9 that used data from 4259 patients. In that study, the significant prognostic factors for non -small cell and small cell lung cancer were age, KPS, presence/absence of extracranial metastases, and the number of brain metastases. The significant prognostic factors for melanoma and renal cell carcinoma were KPS and the number of brain metastases, whereas for gastrointestinal cancers, only KPS was significant. For breast cancer, KPS, breast tumor subtype, and age were significant. 9, 33 We also show that primary site and histology are important factors. We compared our nomogram estimations with DS-GPA 9 and showed that, within each DS-GPA class, there was a wide range of individualized survival probability. However, because 224 patients had sites/ histologies that were not included in the DS-GPA calculation, they were not used for the comparison of nomogram with DS-GPA. In addition, because the level of detail about number of brain lesions varied between the clinical trials used, our nomogram results differed from the DS-GPA, because the DS-GPA showed that different prognostic factors were significant for different diagnoses and that this nomogram did not take that possibility fully into account. The SIR and BS-BM scoring systems have been shown to predict survival among patients with brain metastasis undergoing radiosurgery. Of the 7 RTOG trials, only 1 had a study arm in which patients received radiosurgery. All patients received whole brain radiation. Therefore, a comparison of our nomogram to those systems would be inappropriate. The scoring system developed by Rades et al. is based on the time from diagnosis to initiation of WBRT. This interval was uniform in patients who participated in the RTOG trials because this was one of the elements of the study design for these protocols. Applying this score to this study population would not be informative.
Our nomogram, which included additional variables, allows for individualized estimation of 6-and 12-month survival probabilities and median survival. Our analysis included one of the largest number of patients with brain metastases published to date, with 2350 patients, thereby allowing us the statistical power to examine more variables in our models than could previous models with smaller sample sizes. Our comparison of estimations from the Cox model with those from either RPA or RSF highlighted the potential to tailor predictions to individual patients rather than groups of patients. The RSF estimations were quite different from the Cox model, suggesting that the improvement in accuracy of the Cox model is relevant. Although the Cox model was less than perfect, it remained the most accurate when tested in our data. This nomogram (Fig. 2) can be readily used in clinical practice to provide the patient and their health care team an individualized survival estimate. For each patient, the health care team member records the aforementioned variables. One then draws a line straight upward to the "Points" axis to determine how many points the patient is allocated for each variable. The sum of the individual points for these variables would then be located on the "Total Points axis." A line is drawn straight down to the relevant estimated survival information. This information could then be shared with the patient and could be used to help personalize that patient's care by informing specific treatment decisions over others. For example, if we had a patient with squamous cell lung cancer (57 points), controlled primary disease (0 points), metastatic spread to the brain alone (0 points), aged 80 years (74 points), KPS ≥ 70 (0 points), and only one brain lesion (0 points), their total would be 131 points. Their estimated 6-and 12-month survival probability would be 25% and 8%, respectively, and their projected median survival would be 95 days. To facilitate clinical use of this nomogram, we plan to provide free software for its implementation at http://rcalc.ccf.org, under the category "Brain Cancer".
This study has several limitations. Our data represent a large group of patients with brain metastasis from 7 clinical trials conducted at many sites, and therefore, additional data on the patients' other therapies were not available. Many of the studies incorporated WBRT but not radiosurgery and recent advances in systemic therapies for primary cancers; thus, these data may underestimate survival. Because all these patients developed brain metastases, information from these therapies perhaps might not be significantly deterministic for survival estimation. However, recent improvements in systemic chemotherapy for primary breast, lung, and renal cancers and melanoma would not be reflected in this analysis, because the most recent trial used in this analysis began in 1995. The vast majority of patients in this study had lung cancer (66%), which may limit its applicability to other tumors. Although lung cancer is the most common source of brain metastasis, different primary tumors may behave differently. However, other types of primaries were included in this analysis, although at smaller proportions. The information available on the exact number of brain lesions was clinical trial dependent; thus, for the final nomogram model, the number of brain lesions is categorized as single or multiple to make full use of the available data (79 -16 and 89 -05 the exact number of brain lesions was collected, 85 -28 and 91 -04 only single or multiple was collected, 95 -08 1, 2 or 3 brain lesions was collected, 0118 1, 2, 3 or other brain lesions was collected and 0119 this information was not collected). We readily acknowledge that patients with a varying number of total brain metastases have differing prognoses. 9, 33 Advances in neuroimaging have improved the ability to detect smaller metastatic lesions, which may impact the final nomogram score. To use all available data, missing values in variables of interest were imputed using a widely used multiple imputation procedure, 24, 34 which has been shown to be an effective method for robustly estimating missing values, such that study inference is not biased. 35 -38 Multiple imputation uses the best available information to impute multiple plausible values, then averages these values and adjusts the variance accordingly; thus, study power is increased because all patient data can be used. Lastly, our nomogram is built and validated internally, although we did 10-fold cross validation to control the over-fitting bias. Therefore, this model should ideally be externally validated by additional independent data. However, the methods of nomogram construction that we used have been validated for other diseases using single institutional data. 39 -44 In conclusion, we have developed a tool for assessing individualized survival estimates for patients with brain metastasis. The nomogram provides an individualized estimate of survival, rather than a group estimate. This tool should be useful to patients and health care teams for counseling patients with respect to prognosis. Future directions include external validation in a new dataset and expanding its development in patient cohorts with much greater rates of resection and/or radiosurgery. 
